Ophthotech Corporation (Nasdaq:OPHT) has announced the triggering of a $50 million enrollment milestone payment from Novartis as part of a licensing and commercialization agreement focused on the clinical development of the Ophthotech’s lead compound (“Fovista”) for wet AMD. The payment from Novartis fell due as a result of Ophthotech reaching the first enrollment milestone under the companies’ agreement for a pivotal, multi-national Fovista phase III clinical study and, according to Ophthotech, is the first of a total of $130 million in potential enrollment-based milestones. The compound is expected to be used in combination with anti-VEGF therapy for the treatment of wet AMD.